UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   August 27, 2012

EpiCept Corporation
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-51290 52-1841431
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
777 Old Saw Mill River Rd., Tarrytown, New York   10591
_________________________________
(Address of principal executive offices)
  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   914-606-3500

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Top of the Form

Item 1.01 Entry into a Material Definitive Agreement.

On August 27, 2012, EpiCept Corporation, (the "Company"), together with its wholly-owned subsidiaries Maxim Pharmaceuticals Inc. and Cytovia, Inc., entered in to a First Amendment to Loan and Security Agreement (the "Amendment") with MidCap Funding III, LLC ("MidCap"), as agent for the lenders.

Under the Amendment, the Company agreed to make a principal prepayment of $1.2 million, which approximates the scheduled principal payments due under the Loan and Security Agreement from September 1, 2012 through December 31, 2012. As a result of the prepayment, the current principal balance of the loan is $4.1 million. The next principal payment is due on January 15, 2013, and regularly scheduled monthly principal payments will commence February 1, 2013 until the scheduled maturity of the loan in March 2014. The Company will continue to make monthly payments of interest to the Lender as per the Loan and Security Agreement.

EpiCept also agreed, pursuant to the amendment, to maintain a cash balance of $1.1 million in a bank account that is subject to the security interest maintained by MidCap under the loan agreement. Further, the Company has committed to signing a definitive agreement, acceptable to MidCap, by October 15, 2012 with respect to a sale or partnering transaction and to consummate such a transaction as soon as is practical but in any event no later than January 15, 2013.

The foregoing is a summary of the terms of the First Amendment to Loan and Security Agreement and is qualified in is entirety by reference to the full text of this document, a copy of which is filed as an exhibit to this Current Report.





Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

1. On August 27, 2012, the Company's Board of Directors increased the compensation of Robert W. Cook. Retroactive to his appointment as Interim President and CEO on August 20, 2012, Mr. Cook's annual salary will be $400,000 per annum, with $300,000 per annum payable currently and the balance deferred and payable (on a pro rata basis) upon the completion of certain predetermined objectives, and thereafter payable at the $400,000 per annum level. Mr. Cook's target cash bonus compensation will be 45% of his base salary, the actual amount of which will be determined by the Board. Mr. Cook was also granted 100,000 Restricted Stock Units under the Company's 2005 Equity Incentive Plan, with vesting upon the achievement of certain predetermined objectives prior to March 31, 2013.

2. Effective August 28, 2012, Robert W. Cook has been appointed to EpiCept’s Board of Directors. Mr. Cook has served as EpiCept’s Chief Financial Officer and Senior Vice President, Finance and Administration since April 2004 and was appointed interim President and CEO of EpiCept effective August 20, 2012.

3. Effective August 28, 2012, A. Collier Smyth, Gerhard Waldheim and Wayne P. Yetter resigned from the Company’s Board of Directors. Their resignations were not due to any disagreement with management.





Item 9.01 Financial Statements and Exhibits.

10.1 First Amendment to Loan and Security Agreement with Midcap Funding III, LLC, dated August 27, 2012.
99.1 Press release dated August 30, 2012.
99.2 Press release dated August 31, 2012.






Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    EpiCept Corporation
          
August 31, 2012   By:   /s/ Robert W. Cook
       
        Name: Robert W. Cook
        Title: Interim President and CEO


Top of the Form

Exhibit Index


     
Exhibit No.   Description

 
10.1
  First Amendment to Loan and Security Agreement with Midcap, dated August 27, 2012.
99.1
  Press release, dated August 30, 2012.
99.2
  Press release, dated August 31, 2012.

FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT

THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “ Agreement ”) is dated as of August 27, 2012, by and among EPICEPT CORPORATION , a Delaware corporation (“ EpiCept ”), MAXIM PHARMACEUTICALS INC. , a Delaware corporation (“ Maxim ”), CYTOVIA, INC. , a Delaware corporation (“ Cytovia ”, and collectively with EpiCept and Maxim, the “ Borrowers ”), MIDCAP FUNDING III, LLC , a Delaware limited liability company in its capacity as agent (“ Agent ”) for the lenders under the Loan Agreement (as defined below) (“ Lenders ”), and the Lenders.

W I T N E S S E T H:

WHEREAS , Borrowers, Lenders and Agent are parties to that certain Loan and Security Agreement, dated as of May 27, 2011 (as amended, restated, supplemented or otherwise modified from time to time, the “ Loan Agreement ”; capitalized terms used herein have the meanings given to them in the Loan Agreement except as otherwise expressly defined herein), pursuant to which Lenders have agreed to provide to Borrowers certain loans and other extensions of credit in accordance with the terms and conditions thereof; and

WHEREAS , the Borrowers have requested that the Agent and Lenders amend the Loan Agreement in certain respects and the undersigned Lenders and the Agent are willing to make such amendment, all in accordance with, and subject to, the terms and conditions set forth in, this Agreement.

NOW, THEREFORE, in consideration of the premises, the covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrowers, Lenders and Agent hereby agree as follows:

1.  Acknowledgment of Obligations . Each Borrower acknowledges and agrees that as of the First Amendment Effective Date, but without giving effect to this Agreement, the aggregate principal balance of the Term Loan is at least $5,270,967.80. The foregoing amount does not include interest, fees, expense and other amounts that are chargeable or otherwise reimbursable under the Loan Agreement and the other Loan Documents. Borrowers hereby acknowledge, confirm and agree that all Term Loans made prior to the date hereof, together with interest accrued and accruing thereon, and fees, costs, expenses and other charges owing by Borrowers to Agent and Lenders under the Loan Agreement and the other Loan Documents, are unconditionally owing by Borrowers to Agent and Lenders, without offset, defense or counterclaim of any kind, nature or description whatsoever except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting creditor’s rights generally.

2.  Amendments to the Loan Agreement . Subject to the terms and conditions of this Agreement, including without limitation fulfillment of the conditions to effectiveness specified in Section 8 below, the Loan Agreement is hereby amended as follows:

(a) Section 2.2(b) of the Loan Agreement shall be deleted in its entirety and the following revised Section 2.2(b) shall be substituted in lieu thereof:

“(b) Interest Payments and Repayment . Commencing on the first (1 st ) Payment Date following the Funding Date of Tranche One, and continuing on the Payment Date of each successive month thereafter through and including the Maturity Date, Borrower shall make monthly payments of interest to each Lender in accordance with its respective Pro Rata Share, in arrears, and calculated as set forth in Section 2.3. In addition to the interest payments in accordance with the immediately preceding sentence, Borrower shall make principal payments with respect to the Term Loans as follows: (i) commencing on the Amortization Date, and continuing on the Payment Date of each successive month thereafter through the First Amendment Effective Date, Borrower shall make consecutive monthly payments of principal to each Lender in accordance with its respective Pro Rata Share, as calculated by Agent based upon: (A) the amount of such Lender’s Term Loans and (B) a straight-line amortization schedule ending on the Maturity Date, (ii) on the First Amendment Effective Date, Borrower shall make a principal payment of $1,200,000.00, which payment shall be allocated and paid to each Lender in accordance with its Pro Rata Share, (iii) on January 15, 2013, and on each Payment Date thereafter beginning with February 1, 2013 through the Maturity Date, Borrower shall make principal payments of $277,419.35 on each such date, which payment shall be allocated and paid to each Lender in accordance with its Pro Rata Share and (iv) Borrower shall pay the remaining outstanding balance of the Term Loan on the Maturity Date. Without limiting the foregoing, all unpaid principal and accrued interest with respect to the Term Loans is due and payable in full on the Maturity Date. The Term Loans may be prepaid only in accordance with Sections 2.2(c) and 2.2(d).”

(b) Section 14 of the Loan Agreement shall be amended by adding thereto in appropriate alphabetical order the following definition:

“‘ First Amendment Effective Date ’ has the meaning given such term in the First Amendment to Loan and Security Agreement, dated as of August 27, 2012, among the Borrowers, Agent and Lenders signatory thereto.”

3.  Final Payment Fee . Borrower acknowledges and agrees that, notwithstanding any of the amendments or other modifications set forth herein or in any other documentation or correspondence related to the Loan Agreement or Loan Documents, or any other action taken by Borrower, Agent or any Lender, the Final Payment remains due and payable, in full and without counterclaim or offset of any kind, on the Maturity Date.

4.  Additional Covenants . Until such time as Agent has indicated otherwise in writing, Borrower agrees as follows:

(a)  Pursuit of Acceptable Sale or Partnering Transaction . Borrower shall, and shall cause each of its agents, representatives, officers, directors, employees and advisors, to use its best efforts to (i) negotiate and enter into a definitive agreement with respect to an Acceptable Sale or Partnering Transaction (as defined below) as soon as practical but in any event no later than October 15, 2012 and (ii) consummate such Acceptable Sale or Partnering Transaction as soon as practical but in any event no later than January 15, 2013. An “ Acceptable Sale or Partnering Transaction ” shall mean (i) a sale, merger or similar transaction with respect to Borrower and/or (ii) a partnering transaction in connection with the Borrower’s drug AmiKet (formerly known as EpiCept NP-1), in the case of either or both clause (i) and (ii) on terms and conditions and subject to documentation satisfactory to Agent in its sole discretion, which either (x) provides for the payment in full of the Obligations by not later than January 15, 2013 or (y) provides for the Loans and Loan Documents to remain outstanding on terms and conditions and pursuant to documentation satisfactory to Agent in its sole discretion; provided , that, nothing in this Agreement shall constitute Agent’s or any Lender’s consent to any such transaction or any documentation entered into in connection with any such transaction, all of which remains subject to future consent by Agent and the Lenders.

(b)  Cooperation and Deliverables Relating to Acceptable Sale or Partnering Transaction . Borrower shall deliver to Agent on the first Business Day of each week an officer’s certificate, in form and substance satisfactory to Agent, executed by Borrower’s Chief Financial Officer, that includes (i) a status update and detailed summary with respect to (A) any potential or ongoing partnering transactions in connection with the Borrower’s drug AmiKet (formerly known as EpiCept NP-1), and (B) any transaction or potential transaction with respect to a sale or merger involving the Borrower, in all cases under clause (A) or (B), whether or not the same would constitute an Acceptable Sale or Partnering Transaction and (ii) a certification by Borrower’s Chief Financial Officer, that there have been no adverse changes in connection with discussions, negotiations and circumstances surrounding any such potential transaction, including any circumstances that would either (A) cause such transaction not to constitute an Acceptable Sale or Partnering Transaction or (B) affect in any way the possibility that such transaction is documented by not later than October 15, 2012 or consummated by not later than January 15, 2013. Borrower shall, at the request of Agent, cause all officers, management personnel or other representatives of Borrower (as requested by Agent) to make themselves available to participate in a telephonic or in person meeting to discuss such weekly status update and any such potential transaction.

(c)  Budget Matters . Borrower shall (i) (A) on or prior to the First Amendment Effective Date, deliver to Agent an operating budget in form, substance and methodology satisfactory to Agent, which shall reflect Borrower’s good faith projection of all cash receipts and disbursements on a week-by-week basis in connection with the operating of its business through October 31, 2012, (B) for each month (each a “ Subject Month ”) beginning with the month ending November 30, 2012 and continuing for each month ended thereafter, on or prior to the date that is ten (10) days prior to the beginning of such Subject Month, deliver to Agent an operating budget in form, substance and methodology satisfactory to Agent, which shall reflect Borrower’s good faith projection of all cash receipts and disbursements on a week-by-week basis in connection with the operating of its business for, and through the end of, the Subject Month (the budgets delivered pursuant to clauses (A) and (B) of this Section 4(c)(i) shall be collectively referred to as the “ Budget ”) and (C) on Monday of each week following the First Amendment Effective Date, deliver to Agent an expense report for the immediately preceding week along with a comparison against the budget amount of expenses for that week in accordance with the Budget, and (ii) during any given week, cause its expenditures to be in line with its Budget for such week in all material respects and, in furtherance of the foregoing, with respect to line items in the Budget in excess of $25,000, shall not make expenditures with respect to any line item on the Budget in excess of five percent (5.0%) (or such greater percentage as may be consented to in writing in advance by Agent in its sole discretion (the determination of whether Agent is willing to grant such consent not to be unreasonably delayed)) of the amount set forth on the Budget for such expenditure.

(d)  Cash Management . Without limiting the requirements in the Loan Agreement with respect to Borrower’s Collateral Accounts or otherwise:

  (i)   On or prior to the First Amendment Effective Date (and thereafter with respect to any new Receipts (as defined below), Borrower shall deposit with Agent all of its cash, Cash Equivalents and other items of payment or receipts (such cash, Cash Equivalents and other items of payment or receipts, collectively, the “ Receipts ”) to be held by Agent subject to distribution into the Specified Controlled Operating Account or the Specified Controlled Deposit Account as set forth below.

  (ii)   By not later than August 31, 2012, Borrower shall establish or designate a deposit account in the name of Borrower (the “ Specified Controlled Operating Account ”) with a depositary institution satisfactory to Agent and shall have entered into and caused such depositary institution to enter into a Control Agreement with Agent that governs such Specified Controlled Operating Account, which Control Agreement shall provide that Agent has sole dominion and control over such Specified Controlled Operating Account and that such depositary institution shall, after depositary has received notice from Agent, accept only instructions from Agent, and not Borrower, with respect to the Specified Controlled Operating Account and any and all Receipts on deposit or to be deposited therein. Upon satisfaction of the requirements set forth in the immediately preceding sentence of this subclause (ii) in Agent’s discretion, Agent shall deposit in the Specified Controlled Operating Account a deposit of $675,000 (or such lesser amount as may be on deposit with Agent) of Borrower’s Receipts on deposit with Agent (the “ Initial Budget Expense Funds ”), which shall be maintained on deposit in the Specified Controlled Operating Account except as permitted to be used by Borrower in accordance with Section 4(d)(v) below. Borrower shall not be permitted to deposit any other Receipts into the Specified Controlled Operating Account other than the Specified Funds (as defined below) at such times and for such purposes as are set forth below.

  (iii)   On or prior to September 7, 2012, Borrower shall have established a deposit account (the “ Specified Controlled Deposit Account ”; and together with the Specified Controlled Operating Account, collectively, the “ Specified Controlled Accounts ”), which shall be separate from the Specified Controlled Operating Account, with a depositary institution satisfactory to Agent and shall have entered into and caused such depositary institution to enter into a Control Agreement with Agent that governs such Specified Controlled Deposit Account, which Control Agreement shall provide that Agent has sole dominion and control over such Specified Controlled Deposit Account and that such depositary institution shall, at all times, accept only instructions from Agent, and not Borrower, with respect to the Specified Controlled Deposit Account and any and all Receipts on deposit or to be deposited therein. Upon satisfaction of the requirements set forth in the immediately preceding sentence of this subclause (iii) in Agent’s discretion, Agent shall deposit the remaining balance of Borrower’s Receipts that are on deposit with the Agent into the Specified Controlled Deposit Account. Borrower shall cause any and all future Receipts (other than the Specified Funds (as defined below) used in accordance with the terms of this Agreement) to be deposited into the Specified Controlled Deposit Account.

  (iv)   Beginning on the first Business Day of the week ending November 9, 2012 and on the first Business Day of each week thereafter (each such week, a “ Draw Week ”), so long as (i) no Default or Event of Default shall have occurred and (ii) so long as no event or circumstances exist or have arisen which could reasonably be expected to have a Material Adverse Change, Borrower may request, once during such Draw Week, up to an additional $200,000 (or such lesser amount as may be on deposit with Agent) (the “ Specified Funds ”) to be transferred from the Specified Controlled Deposit Account to the Specified Controlled Operating Account to be used solely to reimburse Borrower for expenses actually incurred and disbursements actually made in accordance with and as set forth in the Budget for the week ended immediately prior to the Draw Week. If such Specified Funds are available, following such request and a determination by Agent in its discretion that such expenses have been incurred or disbursements made in accordance with the Budget, Agent shall instruct the depositary bank where the Specified Controlled Deposit Account is located to transfer the Specified Funds to the Specified Controlled Operating Account. To the extent that any Specified Funds are not used to satisfy such expenses or disbursements, Borrower shall cause such excess funds to be deposited back into the Specified Controlled Deposit Account by the first Business Day of the week immediately succeeding the Draw Week.

  (v)   Borrower shall use the Initial Budget Expense Funds and the Specified Funds solely to satisfy the expenses and disbursements set forth in the Budget and then only in accordance with the procedures set forth in this Agreement. Without limiting the foregoing, Borrower agrees that it shall not, under any circumstances, use any of its Receipts, including without limitation, the Initial Budget Expense Funds and the Specified Funds, to challenge (A) any of Agent’s or any Lender’s Liens under the Loan Agreement and other Loan Documents, (B) any right or remedy Agent or any Lender may have under the Loan Documents or pursuant to applicable law, or (C) the enforceability of any of the Loan Documents.

  (vi)   Borrower hereby authorizes Agent and Lenders to debit any Specified Controlled Account for payment when due of any and all Obligations, including without limitation, principal payments, interest payments, fees and Lenders’ Expenses, due to Agent or any Lender pursuant to the Loan Documents.

(e)  General Cooperation and Disclosure . Without limiting anything in clauses (a) through (d) above or otherwise in this Agreement, Borrower shall, and shall cause its officers, directors, employees and advisors to, cooperate fully with Agent in furnishing information as and when reasonably requested by Agent or any other Lender regarding the Collateral, Borrower’s financial affairs, finances, financial condition, business and operations or any other matters related to the Borrower or otherwise contemplated in this Agreement. Borrower authorizes Agent to meet and/or have discussions with any of its officers, directors, employees and advisors from time to time as reasonably requested by Agent to discuss any matters regarding the Collateral, Borrower’s or any other Credit Party’s financial affairs, finances, financial condition, business and operations, or any other matters related to the Borrower or otherwise contemplated in this Agreement and shall direct and authorize all such persons and entities to fully disclose to Agent all information reasonably requested by Agent regarding the foregoing. Borrower waives and releases any such officer, director, employee and advisor from the operation and provisions of any confidentiality agreement with Borrower, as the case may be, such that such person or entity is not prohibited from providing any of the foregoing information to Agent or any Lender.

5.  Additional Events of Default . Any of the following shall constitute an immediate Event of Default hereunder and under the Loan Agreement: (a) the failure by Borrower to comply with any term, condition or covenant set forth in this Agreement, (b) the failure of any representation or warranty made by Borrower under or in connection with this Agreement to be true, correct and complete as of the date when made or any other breach of any such representation or warranty, (c) the repudiation and/or assertion of any defense by any Borrower with respect to this Agreement or any Loan Document or the pursuit by Borrower or any person related to Borrower against the Agent or any Indemnified Person, (d) the failure by Borrower to deliver the officer’s certificate set forth in Section 4(b) of this Agreement, or the failure of such certificate to include the certifications relating to any possible transaction that could constitute an Acceptable Sale or Partnering Transaction as required by Section 4(b) of this Agreement or (e) a determination by Agent in its sole discretion that (i) discussions, negotiations or progress relating to any potential Acceptable Sale or Partnering Transaction have ceased or slowed or other circumstances or developments have arisen that make it unlikely that such sale or partnering transaction will be consummated or (ii) it is unlikely that Borrower shall be able to document or consummate an Acceptable Sale or Partnering Transaction in a time period acceptable to Agent.

6.  No Other Amendments or Consents, Waivers, Etc.; Reservation of Rights . Except for the amendments and other modifications set forth and referred to in Sections 2 thru 5 above, the Loan Agreement and the other Loan Documents shall remain unchanged and in full force and effect. Nothing in this Agreement is intended, or shall be construed, to constitute a novation or an accord and satisfaction of any of Borrowers’ Obligations or to modify, affect or impair the perfection or continuity of Agent’s security interests in, security titles to or other liens, for the benefit of itself and the Lenders, on any Collateral for the Obligations. Without limiting the foregoing, except as expressly set forth herein, the execution, delivery and effectiveness of this Agreement shall not directly or indirectly (i) create any obligation to make any further loans, advances or other financial accommodations or to continue to defer any enforcement action after the occurrence of any Default or Event of Default, whether such Default or Event of Default has occurred or occurs in the future, (ii) constitute a consent or waiver of any past, present or future violations of any provisions of the Loan Agreement or any other Loan Documents nor constitute a novation of any of the Obligations under the Loan Agreement or other Loan Documents, (iii) amend, modify or operate as a waiver of any provision of the Loan Agreement or any other Loan Documents or any right, power or remedy of any Lender, (iv) constitute a consent to any merger or other transaction or to any sale, restructuring or refinancing transaction or (v) constitute a course of dealing or other basis for altering any Obligations or any other contract or instrument. Except as expressly set forth herein, each Lender reserves all of its rights, powers, and remedies under the Loan Agreement, the other Loan Documents and applicable law. All of the provisions of the Loan Agreement and the other Loan Documents, including, without limitation, the time of the essence provisions, are hereby reiterated, and if ever waived, are hereby reinstated.

7.  Representations and Warranties . To induce Agent and Lenders to enter into this Agreement, each Borrower does hereby warrant, represent and covenant to Agent and Lenders that (i) each representation or warranty of Borrowers set forth in the Loan Agreement is hereby restated and reaffirmed as true and correct in all material respects on and as of the date hereof as if such representation or warranty were made on and as of the date hereof (except to the extent that any such representation or warranty expressly relates to a prior specific date or period) and (ii) each Borrower has the power and is duly authorized to enter into, deliver and perform this Agreement and this Agreement is the legal, valid and binding obligation of each Borrower enforceable against such Borrower in accordance with its terms.

8.  Condition Precedent to Effectiveness of this Agreement . This Agreement shall become effective as of the date (the “ First Amendment Effective Date ”) upon which Agent shall have received the following, each in form and, in form and substance satisfactory to Agent and Lenders:

(a) one or more counterparts of this Agreement duly executed and delivered by Borrowers, Agent and Lenders

(b) the principal payment payable on the First Amendment Effective Date as set forth in Section 2.2(b) of the Loan Agreement (as amended by this Agreement);

(c) satisfaction, in Agent’s sole discretion, by Borrower of all of the conditions set forth in Section 4 of this Agreement that are required to be satisfied on or prior to the First Amendment Effective Date; and

(d) such other documents, instruments, agreements and opinions as the Agent shall request.

9.  Release .

(a) In consideration of the agreements of Agent and Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender and their respective successors and assigns, and their respective present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, Lenders and all such other persons being hereinafter referred to collectively as the “ Releasees ” and individually as a “ Releasee ”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever (individually, a “ Claim ” and collectively, “ Claims ”) of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which any Borrower or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the First Amendment Effective Date, including, without limitation, for or on account of, or in relation to, or in any way in connection with the Loan Agreement or any of the other Loan Documents or transactions thereunder or related thereto.

(b) Each Borrower understands, acknowledges and agrees that its release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.

(c) Each Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.

10.  Covenant Not To Sue . Each Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby absolutely, unconditionally and irrevocably, covenants and agrees with and in favor of each Releasee that it will not sue (at law, in equity, in any regulatory proceeding or otherwise) any Releasee on the basis of any Claim released, remised and discharged by Borrowers pursuant to Section 9 above. If any Borrower or any of its successors, assigns or other legal representatives violates the foregoing covenant, Borrowers, for themselves and their successors, assigns and legal representatives, agree to pay, in addition to such other damages as any Releasee may sustain as a result of such violation, all attorneys’ fees and costs incurred by any Releasee as a result of such violation.

11.  Indemnification . Borrower hereby agrees to indemnify, defend and hold harmless Agent and each Lender in accordance with Section 12.2 of the Loan Agreement, the terms of which are incorporated herein by reference.

12.  Advice of Counsel . Each of the parties represents to each other party hereto that it has discussed this Agreement with its counsel.

13.  Severability of Provisions . In case any provision of or obligation under this Agreement shall be invalid, illegal or unenforceable in any applicable jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.

14.  Counterparts . This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original and all of which when taken together shall constitute one and the same instrument.

15.  GOVERNING LAW . THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF MARYLAND APPLICABLE TO CONTRACTS MADE AND PERFORMED IN SUCH STATE WITHOUT REGARD TO THE PRINCIPLES THEREOF REGARDING CONFLICTS OF LAWS.

16.  Entire Agreement . The Loan Agreement and the other Loan Documents as and when modified through this Agreement embody the entire agreement between the parties hereto relating to the subject matter thereof and supersede all prior agreements, representations and understandings, if any, relating to the subject matter thereof.

17.  No Strict Construction, Etc. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. Time is of the essence for this Agreement.

18.  Loan Document . For the avoidance of doubt, this Agreement constitutes a Loan Document.

19.  Costs and Expenses . Each Borrower absolutely and unconditionally agrees to pay or reimburse upon demand for all reasonable fees, costs and expenses incurred by Agent and the Lenders that are Lenders on the Closing Date in connection with the preparation, negotiation, execution and delivery of this Agreement and any other Loan Documents or other agreements prepared, negotiated, executed or delivered in connection with this Agreement or transactions contemplated hereby.

[ Remainder of page intentionally blank; signature pages follow. ]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year specified at the beginning hereof.

BORROWERS :

EPICEPT CORPORATION

By:       
Name:       
Title:       


MAXIM PHARMACEUTICALS INC.

By:       
Name:       
Title:       


CYTOVIA, INC .

By:       
Name:       
Title:       


AGENT AND LENDER :

MIDCAP FUNDING III, LLC

By:       
Name:       
Title: Authorized Signatory

Contacts

     
EpiCept Corporation:   Investors:
777 Old Saw Mill River Road   LHA
Tarrytown, NY10591   Kim Sutton Golodetz
Robert W. Cook   (212) 838-3777
(914) 606-3500   kgolodetz@lhai.com
rcook@epicept.com    
    or
    Bruce Voss
    (310) 691-7100
    bvoss@lhai.com
Media:
 
Feinstein Kean Healthcare
Greg Kelley
(617) 577-8110
gregory.kelley@fkhealth.com
 



 
 

EpiCept Announces Changes to its Board of Directors

TARRYTOWN, N.Y. (August 30, 2012) – EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that A. Collier Smyth, Gerhard Waldheim and Wayne P. Yetter have resigned from the Company’s Board of Directors, effective August 28, 2012. Their resignations were not as a result of any disagreement with management.

In addition, Robert W. Cook has been appointed to EpiCept’s Board, effective August 28, 2012. Mr. Cook has served as EpiCept’s Chief Financial Officer and Senior Vice President, Finance and Administration since April 2004 and is currently serving as interim President and CEO of EpiCept.

Alan W. Dunton, M.D., Non-Executive Chairman of the Board of EpiCept, commented, “On behalf of EpiCept and its shareholders, I would like to thank Collier, Gerhard and Wayne for their many contributions to the Company and its Board of Directors. We mutually agreed that a reduction in the size of our Board was appropriate at this time as the Company is singularly focused on successfully concluding a strategic transaction in line with the objectives we previously outlined. We will not look to return the membership of the Board to its previous size at this time.”

EpiCept engaged SunTrust Robinson Humphrey in January 2012 to assist in exploring strategic alternatives to maximize the commercial opportunity of AmiKet™ for the treatment of CIPN following taxane-based therapy. The engagement is focused on the identification and implementation of a strategy designed to optimize AmiKet ’s value for the Company’s stockholders, which includes the evaluation of potential transactions involving the sale of the Company.

About EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company’s pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies. The Company’s product Ceplene ® , when used concomitantly with low-dose interleukin-2 (IL-2) is intended as remission maintenance therapy in the treatment of acute myeloid leukemia (AML) for adult patients who are in their first complete remission. The Company sold all of its rights to Ceplene ® in Europe and certain Pacific Rim countries and a portion of its remaining Ceplene ® inventory to Meda AB. Ceplene ® is licensed to MegaPharm Ltd. to market and sell in Israel and EpiCept has retained its rights to Ceplene ® in all other countries, including countries in North and South America. The Company has other oncology drug candidates in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern, the risks associated with our ability to continue to meet our obligations under our existing debt agreements, the risk that Azixa™ will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myrexis, the risk that clinical trials for AmiKet™ or crolibulin TM will not be successful, the risk that AmiKet™ or crolibulin TM will not receive regulatory approval or achieve significant commercial success, the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all, the risk that Ceplene ® will not receive regulatory approval or marketing authorization in the United States or Canada, the risk that Ceplene ® will not achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials, the risk that we will not obtain approval to market any of our product candidates, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.epicept.com . You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

*Azixa is a registered trademark of Myrexis, Inc .

# # #

EPCT-GEN

Contacts

     
EpiCept Corporation:   Investors:
777 Old Saw Mill River Road   LHA
Tarrytown, NY 10591   Kim Sutton Golodetz
Robert W. Cook   (212) 838-3777
(914) 606-3500   kgolodetz@lhai.com
rcook@epicept.com    
    or
    Bruce Voss
    (310) 691-7100
    bvoss@lhai.com
Media:
 
Feinstein Kean Healthcare
Greg Kelley
(617) 577-8110
gregory.kelley@fkhealth.com
 



 
 

EpiCept Amends Loan and Security Agreement

TARRYTOWN, N.Y. (August 31, 2012) – EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that it has amended the Company’s Loan and Security Agreement with MidCap Financial, LLC (“MidCap” or the “Lender”) effective August 27, 2012.

Pursuant to the terms of the amendment, EpiCept has made a principal prepayment of $1.2 million, which approximates the scheduled principal payments due under the Loan and Security Agreement from September 1, 2012 through December 31, 2012. As a result of the prepayment, the current principal balance of the loan is $4.1 million. The next principal payment is due on January 15, 2013, and regularly scheduled monthly principal payments will commence February 1, 2013 until the scheduled maturity of the loan in March 2014. The Company will continue to make monthly payments of interest to the Lender as per the Loan and Security Agreement.

EpiCept also agreed, pursuant to the amendment, to maintain a cash balance of $1.1 million in a bank account that is subject to the security interest maintained by MidCap under the loan agreement. Further, the Company has committed to signing a definitive agreement, acceptable to MidCap, by October 15, 2012 with respect to a sale or partnering transaction and to consummate such a transaction as soon as is practical but in any event no later than January 15, 2013.

“This amendment is consistent with our current plans to complete a transaction and leaves us with cash availability similar to what we had prior to the amendment,” remarked Robert Cook, EpiCept interim President and CEO. “While we cannot be certain that an acceptable transaction can be completed according to this timetable or at all, we are intently focused on concluding a transaction within the deadlines set forth in the amendment.”

EpiCept engaged SunTrust Robinson Humphrey in January 2012 to assist in exploring strategic alternatives to maximize the commercial opportunity of AmiKet™ for the treatment of CIPN following taxane-based therapy. The engagement is focused on the identification and implementation of a strategy designed to optimize AmiKet ’s value for the Company’s stockholders, which includes the evaluation of potential transactions involving the sale of the Company. EpiCept is considering various transactions to obtain additional cash resources to fund operations, including the sale or licensing of assets and the sale of equity securities. Current cash is anticipated to be sufficient to run operations into the fourth quarter of 2012. If EpiCept is unable to complete a transaction or otherwise obtain funding on a timely basis, the Company may default on its loans or be declared in default under the Loan and Security Agreement, which would entitle the Lender to sell the Company’s intellectual property and other assets. See the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2012 for a further discussion of its liquidity and cash position.

About EpiCept Corporation

EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of pain and cancer. The Company’s pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies. The Company’s product Ceplene ® , when used concomitantly with low-dose interleukin-2 (IL-2) is intended as remission maintenance therapy in the treatment of acute myeloid leukemia (AML) for adult patients who are in their first complete remission. The Company sold all of its rights to Ceplene ® in Europe and certain Pacific Rim countries and a portion of its remaining Ceplene ® inventory to Meda AB. Ceplene ® is licensed to MegaPharm Ltd. to market and sell in Israel and EpiCept has retained its rights to Ceplene ® in all other countries, including countries in North and South America. The Company has other oncology drug candidates in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern, the risks associated with our ability to continue to meet our obligations under our existing debt agreements, the risk that Azixa™ will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myrexis, the risk that clinical trials for AmiKet™ or crolibulin TM will not be successful, the risk that AmiKet™ or crolibulin TM will not receive regulatory approval or achieve significant commercial success, the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet™ on attractive terms, a timely basis or at all, the risk that Ceplene ® will not receive regulatory approval or marketing authorization in the United States or Canada, the risk that Ceplene ® will not achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials, the risk that we will not obtain approval to market any of our product candidates, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.epicept.com . You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

*Azixa is a registered trademark of Myrexis, Inc .

# # #

EPCT-GEN